{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:24:33Z","timestamp":1786983873111,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006477","name":"National Taiwan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006477","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytica Chimica Acta"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.aca.2024.342537","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T15:27:11Z","timestamp":1711380431000},"page":"342537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Quantifying payloads of antibody\u2012drug conjugates using a postcolumn infused-internal standard strategy with LC\u2012MS"],"prefix":"10.1016","volume":"1303","author":[{"given":"Chih-Ning","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-9536","authenticated-orcid":false,"given":"Hsiao-Wei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-4056","authenticated-orcid":false,"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aca.2024.342537_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody-drug conjugates: targeted drug delivery for cancer","volume":"14","author":"Alley","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.aca.2024.342537_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.aca.2024.342537_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.aca.2024.342537_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.aca.2024.342537_bib5","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.aca.2024.342537_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbmt.2014.10.025","article-title":"Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy","volume":"21","author":"Othus","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.aca.2024.342537_bib7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.aca.2024.342537_bib8","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4155\/bio-2022-0219","article-title":"Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography\/high-resolution mass spectrometry","volume":"14","author":"Inoue","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.aca.2024.342537_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.122.001135","article-title":"Detection and characterization of in vitro payload-containing catabolites of noncleavable antibody-drug conjugates by high-resolution mass spectrometry and multiple data mining tools","volume":"51","author":"Cai","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.aca.2024.342537_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.aca.2024.342537_bib11","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.aca.2024.342537_bib12","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (sacituzumab govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.aca.2024.342537_bib13","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-Human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.aca.2024.342537_bib14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/chromsci\/bmaa122","article-title":"Simple and rapid LC-MS\/MS methods for quantifying catabolites of antibody-drug conjugates with SMCC linker","volume":"59","author":"Li","year":"2021","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.aca.2024.342537_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpba.2017.06.032","article-title":"LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients","volume":"145","author":"Iwamoto","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.aca.2024.342537_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jpba.2017.01.011","article-title":"LC-MS\/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)","volume":"137","author":"Liu","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.aca.2024.342537_bib17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4155\/bio.13.72","article-title":"PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine","volume":"5","author":"Dere","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.aca.2024.342537_bib18","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1021\/ac990312o","article-title":"Postcolumn introduction of an internal standard for quantitative LC\u2212MS analysis","volume":"71","author":"Choi","year":"1999","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2024.342537_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112956","article-title":"Post-column infused internal standard assisted lipidomics profiling strategy and its application on phosphatidylcholine research","volume":"178","author":"Liao","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.aca.2024.342537_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.aca.2018.02.040","article-title":"Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS\/MS","volume":"1019","author":"Chiu","year":"2018","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.aca.2024.342537_bib21","doi-asserted-by":"crossref","first-page":"10702","DOI":"10.1021\/acs.analchem.9b02050","article-title":"Improved dried blood spot-based metabolomics analysis by a postcolumn infused-internal standard assisted liquid chromatography-electrospray ionization mass spectrometry method","volume":"91","author":"Chepyala","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2024.342537_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.aca.2024.342537_bib23","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.aca.2024.342537_bib24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","article-title":"Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer","volume":"69","author":"Girish","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.aca.2024.342537_bib25","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.aca.2024.342537_bib26","series-title":"Guideline on Bioanalytical Method Validation","year":"2011"},{"key":"10.1016\/j.aca.2024.342537_bib27","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.analchem.9b00118","article-title":"Enhancing sensitivity of microflow-based bottom-up proteomics through postcolumn solvent addition","volume":"91","author":"Distler","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2024.342537_bib28","article-title":"Bioanalytical method validation","year":"2018","journal-title":"Guidance for Industry"},{"key":"10.1016\/j.aca.2024.342537_bib29","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.analchem.9b00118","article-title":"Enhancing sensitivity of microflow-based bottom-up proteomics through postcolumn solvent addition","volume":"91","author":"Distler","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2024.342537_bib30","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/acs.analchem.8b05720","article-title":"Post-column make-up flow (PCMF) enhances the performance of capillary-flow PGC-LC-MS\/MS-Based glycomics","volume":"91","author":"Hinneburg","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2024.342537_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chroma.2013.12.066","article-title":"Using a postcolumn-infused internal standard for correcting the matrix effects of urine specimens in liquid chromatography-electrospray ionization mass spectrometry","volume":"1327","author":"Liao","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.aca.2024.342537_bib32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14712598.2021.1890710","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond","volume":"21","author":"Perez","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.aca.2024.342537_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-014-2500-2","article-title":"Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates","volume":"74","author":"Lu","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.aca.2024.342537_bib34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.aca.2024.342537_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.21037\/atm-21-1103","article-title":"Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?","volume":"9","author":"Santi","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.aca.2024.342537_bib36","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.aca.2024.342537_bib37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Analytica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003267024003386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003267024003386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T16:11:01Z","timestamp":1712765461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003267024003386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"alternative-id":["S0003267024003386"],"URL":"https:\/\/doi.org\/10.1016\/j.aca.2024.342537","relation":{},"ISSN":["0003-2670"],"issn-type":[{"value":"0003-2670","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying payloads of antibody\u2012drug conjugates using a postcolumn infused-internal standard strategy with LC\u2012MS","name":"articletitle","label":"Article Title"},{"value":"Analytica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aca.2024.342537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"342537"}}